# Peptron Gets Phase 1 Approval for Monthly Obesity Drug

> Peptron secures South Korea's Phase 1 approval for once-monthly obesity drug PT403, targeting first dose in December.
- Title: Peptron Gets Phase 1 Approval for Monthly Obesity Drug
- Summary: Peptron secures South Korea's Phase 1 approval for once-monthly obesity drug PT403, targeting first dose in December.
- Keywords: peptron, pt403, smartdepot, semaglutide, south korea's ministry of food and drug, chungnam national university hospital, american diabetes association, phase 1 clinical trial, obesity treatment, once-monthly dosing, markets, BigGo Finance
- URL: https://shortify.news/BigGo_Finance/peptron-gets-phase-1-approval-for-monthly-obesity-drug
- Source: BigGo Finance — https://finance.biggo.com/news/416f7283-bb39-4b9b-90f7-55ac838d9a16
- Author: BigGo Finance
- Published: 2026-11-19T03:26:02+00:00
- Read time: 1 min
- Topics: peptron, pt403, smartdepot, semaglutide, south korea's ministry of food and drug, chungnam national university hospital, american diabetes association, phase 1 clinical trial, obesity treatment, once-monthly dosing, finance, markets
## Peptron Wins Phase 1 Approval
Peptron received approval from South Korea's Ministry of Food and Drug Safety for PT403, a once-monthly obesity treatment candidate.
## PT403 Uses SmartDepot Platform
PT403 applies Peptron's proprietary SmartDepot platform to semaglutide to extend dosing from weekly to monthly.
## First Dose Targeted for December
The company plans to administer the first dose in December after completing follow-up procedures.
## Trial at Chungnam National University Hospital
The Phase 1 trial will evaluate safety, tolerability and pharmacokinetics in 22 healthy adults.
## Preclinical Results at ADA Meeting
Peptron presented preclinical results for PT403 at the American Diabetes Association meeting in June.
## Company's Statement on Approval
A Peptron official said, 'This IND approval is meaningful in that the once-monthly semaglutide formulation produced at our own plant has entered full-scale clinical development.'

> This IND approval is meaningful in that the once-monthly semaglutide formulation produced at our own plant has entered full-scale clinical development.
## Key takeaway

Peptron received South Korea's Ministry of Food and Drug Safety approval for PT403, a once-monthly obesity treatment candidate, with first dose planned for December.

---

Summary: Shortify — https://shortify.news/BigGo_Finance/peptron-gets-phase-1-approval-for-monthly-obesity-drug
Reporting: BigGo Finance — https://finance.biggo.com/news/416f7283-bb39-4b9b-90f7-55ac838d9a16

When you use this summary, link the Shortify URL for the summary and credit the reporting to its newsroom.